WallStreetZenWallStreetZen

NASDAQ: LMAT
Lemaitre Vascular Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Lemaitre Vascular revenue was $262.43M for the trailing 12 months ending Jun 30, 2026, with 38.1% growth year over year. Quarterly revenue for the quarter (Q2 2026) ending on Jun 30, 2026 was $70.4M, up 5.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LMAT annual revenue was $249.6M, with 13.5% growth year-over-year.

LMAT past revenue growth

How has LMAT's revenue growth performed historically?

Company
11.85%
Industry
12.9%
Market
36.16%
LMAT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LMAT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LMAT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LMAT revenue history

Current Revenue
$262.4M
Current Earnings
$65.7M
Current Profit Margin
25%
LMAT's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

Be the first to know when LMAT announces revenue.

LMAT Revenue History By Year

LMAT Yearly RevenueLMAT RevenueLMAT ChangeLMAT Revenue Growth
2025-12-31$249.60M$29.74M+13.53%
2024-12-31$219.86M$26.38M+13.63%
2023-12-31$193.48M$31.83M+19.69%
2022-12-31$161.65M$7.23M+4.68%
2021-12-31$154.42M$25.06M+19.37%
2020-12-31$129.37M$12.13M+10.35%
2019-12-31$117.23M$11.66M+11.05%
2018-12-31$105.57M$4.70M+4.66%
2017-12-31$100.87M$11.72M+13.14%
2016-12-31$89.15M$10.80M+13.78%
2015-12-31$78.35M$7.26M+10.20%
2014-12-31$71.10M$6.55M+10.14%
2013-12-31$64.55M$7.81M+13.77%
2012-12-31$56.74M-$950.00k-1.65%
2011-12-31$57.69M$1.63M+2.90%
2010-12-31$56.06M$5.15M+10.12%
2009-12-31$50.91M$2.19M+4.49%
2008-12-31$48.72M$7.27M+17.55%
2007-12-31$41.45M$6.82M+19.69%
2006-12-31$34.63M$3.90M+12.70%
2005-12-31$30.73M$4.54M+17.35%
2004-12-31$26.18M$5.52M+26.71%
2003-12-31$20.66MN/AN/A

1 of 2

Lemaitre Vascular Revenue FAQ

What was LMAT's revenue last quarter?

On Aug 4, 2026, Lemaitre Vascular (NASDAQ: LMAT) reported Q2 2026 revenue of $70.38 million up 9.57% year over year. In the same quarter last year, Lemaitre Vascular's revenue was $64.23 million.

What was Lemaitre Vascular's revenue in 2025?

Lemaitre Vascular's annual revenue for the twelve months ending Dec 31, 2025 was $249.60 million, a 13.53% increase year over year.

How much does Lemaitre Vascular make in a day?

Based on Lemaitre Vascular annual revenue for the past five years, LMAT makes an average of $536,451.51 per day.

What was Lemaitre Vascular's annual revenue growth in the past year?

As of Q3 2026, Lemaitre Vascular's revenue has grown 11.85% year over year. This is 1.06 percentage points lower than the US Medical Instruments & Supplies industry revenue growth rate of 12.9%. Lemaitre Vascular's revenue in the past year totaled $262.43 million.

How much does Lemaitre Vascular make in a year?

Lemaitre Vascular's revenue by year for the past five years is:
  • Lemaitre Vascular's revenue for the twelve months ending Dec 31, 2025 was $249.60 million, a 13.53% increase year over year.
  • Lemaitre Vascular's annual revenue for Dec 31, 2024 was $219.86 million, a 13.63% increase from 2023.
  • Lemaitre Vascular's annual revenue for 2023 was $193.48 million, a 19.69% increase from 2022.
  • Lemaitre Vascular's annual revenue for 2022 was $161.65 million, a 4.68% increase from 2021.
  • Lemaitre Vascular's annual revenue for 2021 was $154.42 million, a 19.37% increase from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.